ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2015
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02943798 (Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma), which is not on this map. Cited by 153 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study
Who cites it
153 citing papers in PubMed, 1 synthesis or guideline pooled it, 253 citations in OpenAlex.
- Pooled it
- Adjuvant chemotherapy and survival after resection for pulmonary large-cell neuroendocrine carcinoma: a dual-center time-dependent analysis.Translational lung cancer research · 2026Article
- Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy.Science advances · 2026Article
- Patients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER.Cancer reports (Hoboken, N.J.) · 2026Article
- Clinical practice review of systemic treatment in large cell neuroendocrine carcinoma.Translational lung cancer research · 2026Review
- Deep learning based histomorphological phenotyping and prognostic stratification for combined SCLC and LCNEC.NPJ digital medicine · 2026Article
- Article
- Prognostic nomograms for overall and cancer-specific survival in individuals with large cell neuroendocrine carcinoma: a population-based study.Translational cancer research · 2026Article
- Optimal Treatment Strategies for Pulmonary Large Cell Neuroendocrine Carcinoma Based on Molecular Subtypes.Journal of clinical medicine · 2026Article
- Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma.American journal of translational research · 2026Article
- Exceptional long-term survival in pulmonary large-cell neuroendocrine carcinoma with brain metastases: a case report.Frontiers in oncology · 2026Article
- Adjunctive diagnostic utility of POU2F3 in predominantly pulmonary high-grade neuroendocrine carcinomas with limited or discordant conventional marker expression: a case-control study.Frontiers in medicine · 2026Article
- A bibliometric analysis of research trends and global perspectives on lung large cell neuroendocrine cancer.Journal of thoracic disease · 2025Article
- Digital Immunophenotyping of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Subtypes With Specific Tumor-Immune Microenvironment Features.Endocrine pathology · 2025Article
- Large cell neuroendocrine tumor of lung with hemorrhagic cerebral metastasis: A case report.Radiology case reports · 2025Article
- Prognostic models for large cell neuroendocrine lung carcinoma: a machine learning and regression approach.Translational lung cancer research · 2025Article
- Lobectomy versus sub-lobar resection for special type non-small cell lung cancer ≤2 cm.Journal of thoracic disease · 2025Article
- Outcomes with Sublobar Resection vs Lobectomy in Patients With cT1N0M0 Large-cell Neuroendocrine Cancer.Annals of thoracic surgery short reports · 2025Article
- Pulmonary Large-Cell Neuroendocrine Carcinoma, a Multifaceted Disease-Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Combined large cell neuroendocrine carcinoma of the lung: case report with brief review.Indian journal of thoracic and cardiovascular surgery · 2025Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung neuroendocrine tumors are a heterogeneous subtype of pulmonary cancers representing approximately 20% of all lung cancers, including small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). The frequency appears to be approximately 3% for LCNEC. Diagnosis of LCNEC requires attention to neuroendocrine features by light microscopy and confirmation by immunohistochemical staining for neuroendocrine markers. Both SCLC and pulmonary LCNEC are high-grade and poor-prognosis tumors, with higher incidence in males and smokers and peripheral localization. LCNEC is very rare, and the precise diagnosis on small specimens is very difficult, so we have still too few data to define a standard of treatment for pulmonary LCNECs. Data of literature, most based on retrospective analysis, indicated a poor 5-year overall survival, with a high incidence of recurrence after surgery, even in stage I disease. Primary surgery should be the first option in all operable patients because there is no validate therapeutic approach for LCNEC due to lack of clinical trials in this setting. Neoadjuvant platinum-based regimens remain only an option for potentially resectable tumors. In advanced stages, SCLC-like chemotherapy seems the best option of treatment, with a good response rate but a poor overall survival (from 8 to 16 months in different case series). New agents are under clinical investigation to improve LCNEC patients' outcome. We reviewed all data on treatment options feasible for pulmonary LCNEC, both for localized and extensive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.